

**Saskatoon Health Region ANTIBIOGRAM 2016**  
**Pediatric Patients - OUTPATIENTS - All Isolates**  
**January 1, 2016 - December 31, 2016**

**Outpatients – % Susceptible**

	# Isolates tested	Penicillin PO/IV	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cephalixin	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin (urine only)	Gentamicin <sup>3</sup>	Tobramycin	Vancomycin
<b>GRAM-NEGATIVE BACTERIA</b>																									
<i>Escherichia coli</i> <sup>1</sup>	997	54		87	97		90	97		97	97	100	99						93		78	98	95	97	
<i>Enterobacter cloacae</i> <sup>2 †</sup>	16	R		R	94		R	R		81	81	100	88						100		75	44	100	100	
<i>Haemophilus influenzae</i> <sup>‡</sup>	14	50							86	100						100				100	64				
<i>Klebsiella pneumoniae</i> <sup>1</sup>	52	R		99	99		91	100		96	96	100	100						100		94	75	90	92	
<i>Klebsiella oxytoca</i>	33	R		94	100		67	100		100	100	100	100						97		97	91	100	100	
<i>Pseudomonas aeruginosa</i> <sup>2</sup>	61				93						97	79							82				72	75	
<i>Proteus mirabilis</i>	33	76		91	100		82	100		94	94	100	100						100		82	R	94	97	

	# Isolates tested	Penicillin PO/IV	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cephalixin	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin (urine only)	Gentamicin <sup>3</sup>	Tobramycin	Vancomycin
<b>GRAM-POSITIVE BACTERIA</b>																									
<i>Staphylococcus aureus</i> , all																									
- methicillin-susceptible (MSSA)	288			100											82		79	92	96	98	99	99	97		100
- methicillin-resistant (MRSA)	141	R	R	R	R	R	R	R	R	R	R	R	R	R	73		67	93	88	89	99	100	97		100
<i>Staphylococcus epidermidis</i> <sup>‡</sup>	7			R											57		43	100	86	86	R	100	86		100
<i>Streptococcus pneumoniae</i> <sup>‡</sup>	6	83							100	100					83		83			100					100
<i>Enterococcus faecalis</i> , all	117		100				R	R	R	R	R	R					R	R	98	99		99			100

R - intrinsically resistant or less than 25% empiric susceptibility

‡ Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

<sup>1</sup> 1.9 % of E.coli (n=19) and 3.8 % of K.pneumoniae (n=2) were +ESBL (extended spectrum beta-lactamase)

<sup>2</sup> these organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

<sup>3</sup> susceptibility to gentamicin in gram positive organisms refers to combination synergy treatment only